Scarica l'app Stockscreener
28.16
1.33%
-0.38
Dopo l'orario di chiusura:
28.04
-0.12
-0.43%
Precedente Chiudi:
$28.54
Aprire:
$28.24
Volume 24 ore:
1.10M
Relative Volume:
0.75
Capitalizzazione di mercato:
$1.64B
Reddito:
$32.87M
Utile/perdita netta:
$674.31M
Rapporto P/E:
2.4789
EPS:
11.36
Flusso di cassa netto:
$-330.11M
1 W Prestazione:
+3.45%
1M Prestazione:
+3.23%
6M Prestazione:
-22.38%
1 anno Prestazione:
-21.56%
Intervallo 1D:
$27.91
$28.64
Intervallo di 1 settimana:
$26.54
$29.44
Portata 52W:
$22.24
$46.00
Agios Pharmaceuticals Inc Stock (AGIO) Company Profile
Nome
Agios Pharmaceuticals Inc
Settore
Industria
Telefono
617-649-8600
Indirizzo
88 SIDNEY STREET, CAMBRIDGE, MA
Confronta AGIO con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AGIO
Agios Pharmaceuticals Inc
|
28.16 | 1.66B | 32.87M | 674.31M | -330.11M | 11.36 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.68 | 122.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
801.01 | 85.37B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
399.40 | 55.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
795.57 | 50.67B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
170.27 | 37.54B | 447.02M | -1.18B | -906.14M | -6.1812 |
Agios Pharmaceuticals Inc Stock (AGIO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-24 | Iniziato | Truist | Buy |
| 2025-11-20 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2025-11-19 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-02-24 | Iniziato | H.C. Wainwright | Buy |
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-10-10 | Ripresa | Raymond James | Outperform |
| 2024-09-27 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-02-08 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-02-03 | Iniziato | Piper Sandler | Overweight |
| 2022-11-17 | Aggiornamento | Goldman | Sell → Neutral |
| 2022-07-27 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2021-12-03 | Iniziato | BofA Securities | Buy |
| 2021-07-30 | Downgrade | Goldman | Neutral → Sell |
| 2021-07-01 | Iniziato | Raymond James | Mkt Perform |
| 2021-06-10 | Iniziato | H.C. Wainwright | Buy |
| 2021-03-01 | Downgrade | JP Morgan | Overweight → Neutral |
| 2021-03-01 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2021-02-26 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2020-10-22 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2020-03-04 | Iniziato | Barclays | Equal Weight |
| 2019-11-26 | Iniziato | Cantor Fitzgerald | Overweight |
| 2019-09-23 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2019-05-23 | Ripresa | Goldman | Neutral |
| 2019-02-15 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2018-09-25 | Iniziato | Leerink Partners | Mkt Perform |
| 2018-05-23 | Iniziato | Citigroup | Buy |
| 2018-04-11 | Reiterato | Credit Suisse | Outperform |
| 2018-02-15 | Reiterato | Needham | Buy |
| 2018-02-15 | Reiterato | SunTrust | Buy |
| 2017-09-15 | Iniziato | RBC Capital Mkts | Outperform |
| 2017-08-10 | Reiterato | Needham | Buy |
| 2017-08-08 | Reiterato | SunTrust | Buy |
| 2017-08-02 | Aggiornamento | Leerink Partners | Mkt Perform → Outperform |
| 2017-06-26 | Downgrade | Janney | Buy → Neutral |
| 2017-01-17 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2016-10-24 | Iniziato | Needham | Buy |
| 2016-06-13 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2016-05-18 | Reiterato | SunTrust | Buy |
Mostra tutto
Agios Pharmaceuticals Inc Borsa (AGIO) Ultime notizie
What Wall Street predicts for Agios Pharmaceuticals Inc. stock price2025 Analyst Calls & Weekly Setup with High ROI Potential - ulpravda.ru
What RSI levels show for Agios Pharmaceuticals Inc. (8AP) stockEarnings Recap Summary & Detailed Earnings Play Strategies - ulpravda.ru
Market Review: How Agios Pharmaceuticals Inc. stock responds to policy changesJuly 2025 Drop Watch & Technical Buy Zone Confirmation - ulpravda.ru
Why Agios Pharmaceuticals Inc. stock is seen as undervalued2025 Trade Ideas & High Return Trade Opportunity Guides - ulpravda.ru
How Agios Pharmaceuticals Inc. stock reacts to Fed rate cutsJuly 2025 Price Swings & Stepwise Trade Signal Guides - ulpravda.ru
How Agios Pharmaceuticals Inc. stock performs after earnings2025 Market WrapUp & Verified High Yield Trade Plans - ulpravda.ru
What Catalysts Are Rewriting The Story For Agios Pharmaceuticals (AGIO)? - Yahoo Finance
Milanova, Agios Pharmaceuticals CCO, sells $77k in stock - Investing.com
JP Morgan Raises Price Target for Agios Pharmaceuticals (AGIO) to $25 | AGIO Stock News - GuruFocus
Agios Pharmaceuticals, Inc. Being Investigated on Behalf of Agios Pharmaceuticals, Inc. Investors. Contact Levi & Korsinsky For Details - ACCESS Newswire
Agios Pharmaceuticals, Inc. (AGIO): Investor Outlook Highlights A Potential 33% Upside - DirectorsTalk Interviews
Agios to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026 - The Manila Times
Insider Selling: Agios Pharmaceuticals (NASDAQ:AGIO) Insider Sells 2,932 Shares of Stock - MarketBeat
Agios Pharmaceuticals (NASDAQ:AGIO) CFO Sells $79,427.88 in Stock - MarketBeat
Agios Pharmaceuticals (NASDAQ:AGIO) CEO Brian Goff Sells 18,703 Shares - MarketBeat
Agios pharma chief legal officer Burns sells $79k in stock - Investing.com Canada
Agios pharma chief medical officer Gheuens sells $79k in stock - Investing.com Canada
Agios Pharmaceuticals CEO Goff sells $506,663 in stock By Investing.com - Investing.com Canada
Agios Pharmaceuticals CEO Goff sells $506,663 in stock - Investing.com
Jones Cecilia, Agios Pharmaceuticals CFO, sells $79k in stock By Investing.com - Investing.com UK
Agios Pharma shares jump 16% as US FDA expands approval for blood disorder drug - MSN
Momentum Indicator Shows Bearish Divergence in Sylvan Plyboard India LimitedRisk-Reward Ratio Analysis & Stay Ahead With Daily Market Discussions - earlytimes.in
How Agios Pharmaceuticals Inc. stock valuations compare to rivalsStock Correlation Metrics & Free Superior Profit Margins - bollywoodhelpline.com
Agios Pharma jumps 15% as FDA expands use of anaemia drug mitapivat - MSN
Geopolitics Watch: Is Agios Pharmaceuticals Inc 8AP stock attractive post correctionLayoff News & Low Risk Entry Point Tips - moha.gov.vn
FDA approves Agios’ AQVESME (mitapivat) for the treatment of anemia in adults - MSN
Agios Pharmaceuticals (NASDAQ:AGIO) Shares Down 5.3%Should You Sell? - MarketBeat
Capital One Financial To Rally More Than 24%? Here Are Top Analyst Forecasts For Friday - Benzinga
AGIO: Analyst Andrew Berens Raises Agios Pharmaceuticals Price T - GuruFocus
Agios Pharmaceuticals (AGIO) Surges 18.6%: Is This an Indication of Further Gains? - Yahoo Finance
BofA Securities raises Agios Pharma stock price target on FDA approval - Investing.com India
Agios (AGIO) Gets 18.6% Boost from Aqvesme OK - Finviz
B of A Securities Maintains Agios Pharmaceuticals (AGIO) Buy Recommendation - MSN
Agios Pharmaceuticals price target raised to $34 from $32 at BofA - Yahoo Finance
Agios Stock (+19%): AQVESME Thalassemia Approval Ignites Re-Rate - Trefis
Agios Pharma shares jump as US FDA expands approval for blood disorder drug - wibqam.com
Why Agios Pharmaceuticals (AGIO) Is Up 14.6% After First-in-Class Thalassemia Drug AQVESME Wins FDA Approval - Sahm
FDA approves Agios Pharmaceuticals’ Aqvesme in anemia patients - MSN
Agios Pharma stock price target raised to $62 from $48 at H.C. Wainwright - Investing.com India
Truist Financial Forecasts Strong Price Appreciation for Agios Pharmaceuticals (NASDAQ:AGIO) Stock - MarketBeat
Agios Pharma Stock: A Buy After FDA Approves Aqvesme (NASDAQ:AGIO) - Seeking Alpha
Here's Why Shares in Agios Pharmaceuticals Popped Today - AOL.com
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Here's Why Shares in Agios Pharmaceuticals Popped Today - The Motley Fool
Agios Pharmaceuticals, Inc. (AGIO) Discusses FDA Approval of AQVESME for Anemia in Alpha and Beta ThalassemiaSlideshow (NASDAQ:AGIO) 2025-12-24 - Seeking Alpha
First oral anemia treatment across thalassaemia types approved in USA - The Pharma Letter
AGIO's Mitapivat Gets FDA Nod for Thalassemia Indication with REMS in Label - Eastern Progress
Agios Pharma shares jump as US FDA expands approval for its blood disorder drug - Yahoo Finance
Agios Pharmaceuticals (NASDAQ:AGIO) Shares Gap Up on Analyst Upgrade - MarketBeat
Agios Pharmaceuticals Inc Azioni (AGIO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.80%
4.56%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):